The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced it has submitted a new drug application (NDA) to the Food and Drug Administration (FDA) for the use of Xarelto (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment…